Combination therapy in dyslipidemia [electronic resource] / Maciej Banach, editor.
Banach, Maciej, editor.
2015
RC632.D87
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Combination therapy in dyslipidemia [electronic resource] / Maciej Banach, editor.
ISBN 9783319204338 electronic book
3319204335 electronic book
9783319204321
Published Cham, Switzerland : Springer, 2015.
Language English
Description 1 online resource : illustrations
Call Number RC632.D87
Dewey Decimal Classification 616.3997
Summary Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
Bibliography, etc. Note Includes bibliographical references.
Access Note Access limited to authorized users.
Added Author Banach, Maciej, editor.
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Foreword
Statins and bile acid resins
is there a place for such a combination?
Statins and fibrates
should it be recommended?
Statins and ezetimibe
doubts or bright future?
Statins and niacin
the end of residual risk therapy?
Statins and omega-3 fatty acids
what more do we need?
Statins and CETP inhibitors
anacetrapib and evacetrapib
the last hope?
Statins and mipomersen
the issue of tolerability?
Statins and lomitapide
a suitable response for HoFH
Statins and PCSK9 inhibitors
defining the correct patients
Other possible drug combination for dyslipidaemia
Statins and nutraceuticals/functional food
Could be they combined?
Lipid lowering therapy and apheresis
indications and outcomes
Combination of lipid lowering agents with antihypertensive drugs
a joint fight against the two most important risk factors?
Not only dyslipidaemia therapy
the time for polypills
Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom?
Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance?
Conclusions and Take Home Message.

Browse Subjects

Show more subjects...

Statistics

from
to
Export